Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells by Binder, Mascha et al.
Stereotypical Chronic Lymphocytic Leukemia B-Cell
Receptors Recognize Survival Promoting Antigens on
Stromal Cells
Mascha Binder1, Barbara Le´chenne1, Ramesh Ummanni1, Christan Scharf2, Stefan Balabanov1, Maria
Trusch3, Hartmut Schlu¨ter3, Ingke Braren4, Edzard Spillner4, Martin Trepel1*
1Department of Oncology and Hematology, Hubertus Wald Tumorzentrum/University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany, 2Department of Otorhinolaryngology, University of Greifswald, Greifswald, Germany, 3Department of Clinical Chemistry, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, 4Department of Chemistry, University of Hamburg, Hamburg, Germany
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Survival of CLL cells depends on
their close contact with stromal cells in lymphatic tissues, bone marrow and blood. This microenvironmental regulation of
CLL cell survival involves the stromal secretion of chemo- and cytokines as well as the expression of adhesion molecules.
Since CLL survival may also be driven by antigenic stimulation through the B-cell antigen receptor (BCR), we explored the
hypothesis that these processes may be linked to each other. We tested if stromal cells could serve as an antigen reservoir
for CLL cells, thus promoting CLL cell survival by stimulation through the BCR. As a proof of principle, we found that two CLL
BCRs with a common stereotyped heavy chain complementarity-determining region 3 (previously characterized as ‘‘subset
1’’) recognize antigens highly expressed in stromal cells – vimentin and calreticulin. Both antigens are well-documented
targets of autoantibodies in autoimmune disorders. We demonstrated that vimentin is displayed on the surface of viable
stromal cells and that it is present and bound by the stereotyped CLL BCR in CLL-stroma co-culture supernatant. Blocking
the vimentin antigen by recombinant soluble CLL BCR under CLL-stromal cell co-culture conditions reduces stroma-
mediated anti-apoptotic effects by 20–45%. We therefore conclude that CLL BCR stimulation by stroma-derived antigens
can contribute to the protective effect that the stroma exerts on CLL cells. This finding sheds a new light on the
understanding of the pathobiology of this so far mostly incurable disease.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most prevalent type
of leukemia [1,2]. This incurable disease most commonly consists
of malignant B-cells expressing common B-cell markers as well as
monoclonal membrane immunoglobulin, the B-cell receptor for
antigen (BCR) [3]. Major progress has been made in understand-
ing the functional role of the BCR as well as the microenviron-
ment in CLL pathobiology, providing crucial insights into the
biology of this cancer in recent years.
In lymphatic tissues and the bone marrow, CLL cells are in
close contact with a connective tissue network of mesenchyma-
derived stromal cells [4,5,6] including mesenchymal marrow
stromal cells [7,8], CD68+ monocyte-derived nurse-like cells
(NLC)[4], and follicular dendritic cells [9]. This supportive
hematopoietic microenvironment protects CLL cells from spon-
taneous and drug-induced apoptosis [4] and is therefore studied as
a novel drug target in CLL [6,10,11]. The CLL-stroma contact is
mediated primarily by cytokine receptors and adhesion molecules.
One major cytokine axis involves the microenvironmental
expression and secretion of stromal cell-derived factor-1 (SDF-1)
and CXCL13 which bind to the respective cytokine receptors on
CLL cells, promoting migration and survival in CLL cells. In
addition to classical cytokines, stromal cells secrete hedgehog
ligands, which promote survival in CLL cells, as well as a range of
anti-apoptotic membrane proteins such as B-cell-activating factor
of the tumor necrosis factor family (BAFF), the proliferation-
inducing ligand APRIL [12], and CD31 [13]. CLL-stroma
adhesion is largely mediated by integrins, particularly VLA-4
(CD49d), which attaches to stromally expressed VCAM-1 and
fibronectin [14,15,16]. The complex cross-talk between CLL cells
and their protective environment has recently been reviewed
comprehensively [6].
Microenvironmental stimuli by adhesion molecules and cyto-
kines seem not to be the only factors promoting survival of B-CLL
cells. There is emerging evidence that the development and course
of this disease may also be driven by antigenic stimulation through
the BCR [17,18,19,20,21]. Our current understanding of the
configuration of BCRs in CLL strongly supports this hypothesis.
During normal B-cell development, genetic recombination of
various immunoglobulin-encoding genes and somatic hypermuta-
tion shape BCRs and their highly variable complementarity-
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determining regions 3 (CDR3) such that each B-cell recognizes a
particular antigen. If the development of the malignant CLL clone
occurred independently of antigenic interaction, one would expect
the gene usage and CDR3 sequences (the most individual antigen-
binding part of the immunoglobulin) of CLL BCRs to be
randomly distributed as in normal B-cells. However, the CLL
immunoglobulin gene usage is biased [22,23,24,25] and a number
of highly similar CDR3 regions are expressed. Indeed, more than
26% of CLL cells express BCRs belonging to one of almost 150
stereotyped subsets with virtually identical CDR3 sequences
characterized so far [19,20,24,26,27,28]. Thus, one could
postulate that at least CLL cases with stereotyped BCRs recognize
a limited number of epitopes as part of certain antigens that may
therefore trigger and/or sustain the disease through B-cell-
receptor-mediated cell activation. Indeed, CLL BCRs react with
recurring self-antigens in vitro, including IgG, thyroglobulin, DNA,
actin, cardiolipin and others as well as with microbial antigens
and epitopes exposed on cell surfaces as a result of apoptosis
[29,30,31,32,33].
Although microenvironmental stimulation and antigenic drive
through the BCR have been studied mainly as independent
phenomena, there is some recent evidence that these processes
may actually be linked in a broader concept of CLL pathogenesis
and progression. Burger et al. [34] found that CLL cells upregulate
the expression of the chemoattractants CCL3 and CCL4 when co-
cultured with NLCs. This upregulation could be inhibited by
blocking BCR signaling with a specific Syk inhibitor, suggesting
that antigenic stimulation through the BCR had caused CCL3/4
upregulation under co-culture conditions. Moreover, the pro-
survival effects of nurse-like cells could be abrogated by blocking
BCR signaling with a Syk inhibitor [35].
Here we set out to test the hypothesis if stromal cells could serve
as an antigen reservoir for CLL cells, thus promoting CLL cell
survival by stimulation through the BCR. We found that CLL
BCRs expressing a stereotyped heavy chain complementarity-
determining region 3 (HCDR3) can recognize the antigens
vimentin and calreticulin which are highly expressed in stromal
cells. We showed that the cytoskeletal protein vimentin is displayed
on the surface of viable NLCs and that this BCR interaction
contributes to stroma-mediated anti-apoptotic effects. Our results
indicate that, in addition to the known effects of survival factors
and adhesion molecules, stroma-mediated protection from apop-
tosis can be achieved through CLL BCR stimulation by stroma-
derived antigens.
Materials and Methods
Ethics statement
Blood samples with clinical and laboratory features of CLL were
taken after written informed consent as approved by the
University of Freiburg’s institutional review board. Clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
Primary CLL cells, cell lines, culture conditions and
generation of nurse-like cells
Peripheral mononuclear cells (PBMC) from the blood of
patients with CLL were purified by Ficoll separation and directly
used for experiments. Alternatively, PBMCs were resuspended in
90% fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO)
and stored in liquid nitrogen until use. Primary CLL cells were co-
cultured on a feeder layer of M210B4 murine stromal cells in
RPMI medium supplemented with 10% FCS and 1% penicillin/
streptomycin for up to one week. Alternatively, transfected HEK
293T cells were used as feeder layer as described below.
HEK293T cells, HeLa cells and MCF-7 cells were purchased
from the American Type Culture Collection (ATCC) and cultured
in DMEM medium supplemented with 10% FCS and 1%
penicillin/streptomycin.
To generate nurse-like cells (NLC) from the blood of patients
with CLL, purified PBMCs were resuspended in RPMI medium
supplemented with 10% FCS and 1% penicillin/streptomycin at a
density of 16107 cells/ml and cultured in cell culture flasks
(175 cm2) for 14 days. Adherent NLCs appeared on the bottom of
the flask between seven and 14 days of culture and could be
separated from CLL cells in suspension by washes with PBS.
Recombinant expression of BCRs as IgG1 antibody
Immunoglobulin heavy and light chain sequences of a cohort of
CLL patients were determined by anchored PCR cloning into the
TOPO TA vector (Invitrogen) as previously described [36,37].
Patients with the code 014 and 044 belonged to stereotyped subset
1, 022 belonged to subset 3 and 015 belonged to subset 7 described
by Stamatopoulos [19] and Murray [38] and were therefore
chosen for further analysis. Variable heavy and light chain genes
from patient 014, 044 and 022 were amplified from cDNA by
PCR with clone-specific primers and cloned into the mammalian
expression vector pBUD opti human kappa containing the human
IgG1 kappa constant regions [39]. As the CLL clone of patient
015 expressed a lambda light chain, its variable regions were
cloned into pBUD opti human lambda containing the human IgG1
lambda constant regions. To generate a control BCR, random
variable heavy and light chain regions were cloned into pBUD opti
human kappa. The resulting immunoglobulin was designated as
IgGr. After transfection into HEK293T cells and positive selection
with zeocin (100 mg/ml), recombinant BCRs (termed Ig014,
Ig044, Ig022, Ig015 and IgGr) were affinity purified from
supernatant using protein-A sepharose as previously described
[40].
Preparation of protein extracts from cells
Adherent cells were chemically detached from the culture flask
with trypsin, washed once with PBS, pelleted and resuspended in
up to 1 ml of RIPA protein extraction buffer (50 mM Tris-HCl,
pH 7.4, NP-40 1%, Na-deoxycholate 0.25%, 150 mM NaCl,
protease inhibitor), depending on the number of pelleted cells.
After 30 minutes of incubation on ice, the protein extract was
cleared from insoluble material by centrifugation at full speed in a
table centrifuge. Protein concentrations were determined by
Bradford assay (Bio-Rad) following the manufacturer’s instruc-
tions.
One-dimensional and two-dimensional gel
electrophoresis
For one-dimensional gel electrophoresis protein extracts (5 mg),
prepared as described above, were resuspended in a conventional
protein sample buffer containing beta 2-mercaptoethanol as
reducing agent, heated at 95uC for 5 minutes to denature proteins
and loaded on a 10% SDS PAGE gel. Electrophoresis was
performed using the PROTEANH Mini Cell system (Bio-Rad)
with constant voltage (80 V) at 20uC.
For two-dimensional gel electrophoresis, isoelectric focussing
(IEF) was performed with 7 cm pH 4–7 IPG strips (GE
Healthcare) according to the manufacturer’s instructions with
minor modifications to improve resolution. Briefly, 30 mg protein
extracts prepared as described above were diluted to 125 ml with
rehydration buffer (8 M urea, 2 M thiourea, 2% CHAPS, 50 mM
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DTT with 0.5% v/v IPG buffer pH 4–7, [GE Healthcare]) and
used to passively rehydrate each IPG strip overnight. Proteins were
separated by the PROTEAN IEF system (Bio-Rad) at 20uC. The
focusing was started at 250 V for 30 minutes, and then increased
to 5000 V with 5000 Vh linear gradient. The samples were
maintained at 5000 V until a total run of 12 kVh. After IEF, the
IPG strips were equilibrated (10 minutes) in equilibration buffer
(0.375 M Tris-HCl, pH 8.8, 6 M urea, 20% glycerol, 2% SDS
and 130 mM DTT) and then transferred to equilibration buffer
containing 135 mM iodoacetamide (10 minutes) with constant
shaking. The equilibrated strip was applied onto the top of a
12.5% SDS-PAGE gel and sealed with 1% agarose prepared in
SDS-Tris-glycine buffer with trace amounts of bromophenol blue
as a tracking dye to monitor electrophoresis. Electrophoresis was
performed as described for one-dimensional gel electrophoresis.
Gels from one- or two-dimensional gel electrophoresis were
subjected to Coomassie brilliant blue staining or to western
blotting.
Coomassie brilliant blue staining
Gels were soaked with coomasie colloidal staining solution
(Serva) for 2 hours or overnight. Then gels were de-stained in a
solution containing 10% methanol and 7% acetic acid to remove
background staining.
Western blotting
After electrophoresis, proteins were transferred to polyvininy-
lidene difluoride (PVDF) membranes. After electroblotting mem-
branes were blocked with Tris-buffered saline (TBS) 0.1% Tween
20 containing 5% nonfat dry milk and 1% BSA for 1 h at room
temperature. The membranes were incubated overnight at 4uC
with a recombinant CLL BCR as primary antibody (100 mg
antibody/10 ml blocking buffer). After washing in TBS 0.1%
Tween 20, membranes were incubated with a goat anti-human
IgG antibody (Dianova) diluted 1:20000 in blocking buffer for two
hours. After a second washing step, membranes were incubated
for two hours with a horseradish peroxidase-conjugated rabbit
anti-goat IgG antibody. For detection of vimentin, membranes
were incubated for two hours with a commercially available
vimentin antibody (clone M44314F, Meridian Life science) diluted
1:5000 in blocking buffer. followed by secondary detection with a
horseradish peroxidase-conjugated anti-mouse IgG antibody
(Santa Cruz Biotechnology) diluted 1:20 000 in blocking buffer.
Immunodetection was performed using the ECL western blot
analysis system (GE Healthcare), followed by autoradiography on
ECL Hyperfilms (GE Healthcare).
Protein identification by MALDI TOF/TOF
Coomassie-stained two-dimensional electrophoresis gels and
immunoblots were scanned (Bio-Rad) and analyzed by Delta 2D
software (Decodon). The proteomic profile of proteins from nurse-
like cells (NLC) was used as a reference map for spot analysis.
Spots on 2D western blots were overlayed with the reference map,
and matching spots were excised for protein identification by mass
spectrometry. Preparation of peptide mixtures for MALDI-TOF-
TOF and the MALDI-TOF measurement of spotted peptide
solutions was carried out on a 4800 MALDI TOF/TOFTM
Analyzer (Applied Biosystems) as described previously [41].
Protein identification by LC–ESI–Ion trap analysis
For tryptic digestion, coomassie stained protein spot was cut
into small pieces. Gel pieces were incubated and shaken with the
following solutions: swelling solution (100 mM ammonium
carbonate) for 5 min, shrinking solution (50 mM ammonium
carbonate, 60% acetonitrile) for 30 min, swelling solution for
20 min and shrinking solution for 30 min. Gel pieces were dried
by vacuum and rehydrated in 20 ml digestion buffer (10 ng/ml
modified trypsin (Promega) in 50 mM ammonium carbonate,
10% acetonitrile). Samples were incubated at 37uC for 16 h.
Tryptic peptides were extracted by incubating twice with 65%
acetonitrile/5% formic acid for 30 min on the shaker and
sonification for 5 min followed by incubation in 100% acetonitrile.
All supernatants were collected in a new tube and dried under
vacuum. Tryptic peptides were dissolved in 1.5 ml of 50%
acetonitrile and diluted with 13.5 ml of 0.2% formic acid.
Identification was performed on an Agilent 1100 LC/MSD-trap
XCT series system. The electrospray ionization system was the
Chip Cube system using a Large capacity Chip (Agilent
Technologies, Waldbronn, Germany). Sample loading (8 mL/
sample) from the microtiter plate into the enrichment column was
performed at a flow rate set to 4 mL/min with the mix of the two
following mobile phases at a ratio 98:2 (mobile phase A: 0.2%
formic acid in H2O; mobile phase B: 100% ACN). LC gradient
was delivered with a flow rate of 400 nL/min. Tryptic peptides
were eluted from the reversed phase column into the mass
spectrometer using a linear gradient elution of 2–40% B in
40 min. For MS experiments, following mode and tuning
parameters were used: Scan range: 300–2000 m/z, polarity:
positive, capillary voltage: 1900 V, flow and temperature of the
drying gas were 4 L/min and 325uC. The MS/MS experiments
were carried out in auto MS/MS mode using a 4 Da window for
precursor ion selection, an absolute threshold of 10,000, after 3
MS/MS spectra, the precursor ion were excluded from fragmen-
tation for at least one minute. The generic files for database
searching were generated by Data Analysis software version 3.4,
for precursor ion selection a threshold of 5 S/N was applied and
the absolute number of compounds was restricted to 1000 per
MS/MS experiment. Protein identification was performed with
Mascot software[42]. MS/MS datasets were used to search the
spectra against the human subset of the Swiss-Prot database[43].
Immunoprecipitation of vimentin
To immunoprecipitate vimentin from protein extracts, 5 mg of
the CLL BCR Ig014 were incubated for 3 hours at 4uC on a
rocking platform with different protein extracts in a total volume
of 500 ml (concentration of protein extracts 2 mg/ml). Per
reaction, 20 ml of 50% sepharose-G slurry was washed in PBS
twice, added to the reaction and incubated for another 30 minutes.
Sepharose-G beads were pelleted at 500 rounds per minute (rpm)
in a table centrifuge and washed twice with PBS. The beads were
resuspended in sample buffer and subjected to one-dimensional
SDS PAGE as described above. The presence of immunoprecip-
itated material, respectively vimentin, was determined by western
blot analysis using Ig014 or an anti-vimentin antibody for
detection.
Immunofluorescence and confocal microscopy
M210B4 cells were seeded on coverslips (12 mm, Glaswar-
enfabrik Karl Hecht) in 24-well plates at a density of 16105 cells/
ml. Cells were permitted to adhere and expand on the coverslip
over one to three days until about 70% confluent. Cells were fixed
with 4% paraformaldehyde and permeabilized with 0.5% Triton-
X-100. The permeabilization step was omitted if antigens on the
extracellular side of the plasma membrane should be detected.
Fixed cells were blocked with 3% bovine serum albumin (BSA) in
phosphate buffered saline (PBS). Stainings were performed using a
rabbit anti-vimentin antibody (clone H-84, Santa Cruz Biotech-
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nology) at 10 mg/ml and a secondary Fluorescein Isothiocyanate
(FITC)-conjugated goat anti-rabbit IgG antibody (Santa Cruz
Biotechnology) at 4 mg/ml. The CLL BCR Ig014 was used at a
concentration of 100 mg/ml followed by a secondary FITC-
conjugated rabbit anti-human IgG antibody (Sigma) diluted
1:1000. Cell membranes and cytoplasm were counterstained with
Alexa Fluor 594 phalloidin (Invitrogen) and mounted with
VectaShield mounting medium (Vector Laboratories). Coverslips
were fixed on a 76626 mm slide (Roth). Images were obtained by
confocal microscopy (Leika TCS SP2 AOBS; lens 63x) and
analyzed using Leika confocal software.
To analyze the percentage of apoptotic cells, stromal cells were
stained with 7-aminoactinomycin (7-AAD) on the immunofluo-
rescence slides at different time points. Nuclei were counterstained
with 49,6-Diamidino-2-phenylindol (DAPI, Vector Laboratories).
Images were obtained by conventional fluorescence microscopy
(Carl Zeiss, Axioplan).
Measurement of CLL apoptosis on feeder layers
CLL cells were cultivated alone or on a layer of M210B4
murine stromal cells blocked with either Ig014, the control BCR
IgGr, or a commercially available rabbit anti-mouse/human
vimentin antibody (clone H-84, Santa Cruz Biotechnology) at
100 mg/ml. The viability of CLL 014 cells was assessed after six
days of co-culture by trypan blue staining or by fluorescence-
activated cell sorting (FACS) using 7-aminoactinomycin (7-AAD)
or (PI) and annexin V. For trypan blue staining, an aliquot of CLL
cells was taken from the well, diluted 1:10 in 0.4% trypan blue
solution (Gibco) and trypan blue stained and unstained cells were
counted after five minutes in a Neubauer counting chamber. Cell
counts of four quadrants were used to calculate the percentage of
viable cells. For FACS analysis, CLL cells were stained and
measured according to the FITC Annexin V Apoptosis Detection
Kit protocol (BD Pharmingen).
Alternatively, CLL cells were cultured on a feeder layer of
vimentin secreting HEK 293T cells. Therefore, RNA was
extracted from HEK 293T cells (using the Quiagen RNeasy kit)
and cDNA was generated by reverse transcription using oligo(dT)
primers (invitrogen). Subsequently, the vimentin encoding gene
was amplified with gene-specific primers and cloned into the
eukaryotic secretory expression vector pSectag2hygro C (invitro-
gen). HEK 293T cells were transfected with the vimentin encoding
vector and vimentin secretion was verified by western blot analysis
of the supernatant. CLL cell apoptosis was measured at different
time points after co-culture on HEK 293T cells transfected
with vimentin encoding pSectag2hygro C or the empty control
vector.
Results
CLL B-cell receptors with common stereotypical
configuration recognize stromal cell antigens
We tested the hypothesis that CLL B-cell receptors (BCR) may
recognize antigens expressed on stromal cells. Therefore, we
investigated the reactivity of a small set of recombinantly expressed
CLL BCRs with protein extracts from stromal cells. All CLL
BCRs used for this analysis expressed stereotyped heavy chain
complementarity-determining region 3 (CDR3) sequences fre-
quently found in CLL patients (subset 1, 3 and 7 according to
Stamatopoulos [19] and Murray [38]). Table 1 summarizes BCR
gene usage, CDR3 sequence, and mutational status of the four
CLL BCRs used for this study. For protein extraction, we used
primary nurse-like cells (NLCs) from the blood of CLL patients
and the murine stromal cell line M210B4 alone or after co-culture
with primary CLL cells. Extracted proteins of these cells were
subjected to one-dimensional gel electrophoresis. The reactivity of
the CLL BCRs Ig014, Ig015 and Ig022 as well as control IgG with
proteins from the cell extracts was tested by Western blot analysis
using the respective BCR as primary antibody, followed by HRP-
based secondary detection. We found that the CLL BCR named
"Ig014", which belonged to the stereotyped subset 1, recognized a
range of proteins sized between 45 and 57 kDa that were
expressed in the NLC extract and the stromal cell extracts (Figure
S1). To identify the stromal proteins recognized by CLL BCR
Ig014, the NLC protein extract was subjected to two-dimensional
gel electrophoresis (Figure 1A). After electroblotting to a membrane
and development with Ig014 and an HRP-conjugated
secondary antibody, 26 spots were detected (Figure 1B, left
Western blot) that corresponded in size to the bands detected in
the one-dimensional gel electrophoresis. The isoelectric pH
values (pI) of the detected spots ranged from 4.5 to 5.5. All
protein spots were detectable in an independently performed
two-dimensional electrophoresis by Coomassie blue staining,
indicating that the proteins were abundantly expressed in NLCs.
A magnified overlay of the Western blot and the corresponding
Coomassie gel run in parallel is shown in Figure 1C (left panel)
with all overlapping spots depicted in brown and black. The
spots were excised and proteins were analyzed by mass
spectrometry. Twenty-two of the 26 protein spots were
identified as vimentin by MALDI TOF/TOF. The remaining
four spots did not give any results, indicating that the amount of
protein recovered from these spots was too low. The number
and position of the detected spots reflect numerous posttrans-
lational modifications of vimentin such as phosphorylation and
citrullination, which have been previously described for this
Table 1. Characteristics of CLL B-cell receptors cloned as IgG1 antibodies.*
Ig Code Isotype VH Gene VL Gene HCDR3 Sequence subset** Mutation Status VH
Ig014 m, k 1-2 3-20 CARDQWLTLGNYFDYW 1 UM
Ig044 m, k 1-3 1-39 CARDQWLVLGMVFDYW 1 UM
Ig015 m, l 1-69 3-9 CARAVQEDYDFWSG
YYPNYYYYGMDV
7 UM
Ig022 m, k 1-69 1-39 CAREQPDIVVVPADV
GYYYGMDV
3 UM
*CLL denotes chronic lymphocytic leukemia, VH or VL are the genes used for the variable heavy or light chain of the BCR; HCDR3 = heavy chain complementarity-
determining region 3; M= mutated; UM = unmutated.
**Subset of HCDR3 according to Stamatopoulos et al. (2007) and Murray et al. (2008).
doi:10.1371/journal.pone.0015992.t001
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protein [44,45,46]. Table 2 shows protein scores and peptide
counts for each analyzed spot.
To confirm that CLL BCRs using the stereotyped subset 1
HCDR3 region recognize vimentin, we tested the binding of
another CLL BCR of this subset (Ig044) to the NLC protein
extract. As indicated in Table 1, Ig014 and Ig044 express the same
HCDR3 region whereas they differ in their heavy- and light-chain
gene usage. Indeed, like Ig014, Ig044 recognized the spots
previously characterized as vimentin (Figure 1A-C, right panels).
In addition to these spots, Ig044 recognized another protein highly
expressed in NLCs (Figure 1C, right panel, spot 27). This protein
was identified as calreticulin by ESI-ion trap analysis (Table 2).
Figure 1. Subset 1 CLL B-cell receptors Ig014 and Ig044 recognize proteins highly expressed in nurse-like cell extracts. A: Two-
dimensional gel electrophoresis of nurse-like cell protein extracts. Protein samples were prepared and electrophoresis was performed. The gel was
subjected to Coomassie blue staining. pI = isoelectric pH value, M.Wt. = molecular weight. The rectangles indicate the areas magnified in C. B: CLL
B-cell receptors Ig014 and Ig044 recognize partially overlapping protein spots in two-dimensionally separated nurse-like cell protein extracts. Gels run
in parallel to the ones shown in Figure 1A were subjected to Western blotting using Ig014 and Ig044 as primary antibodies, followed by secondary
detection with a horseradish peroxidase-conjugated antibody. A set of protein spots ranging from 45 to 57 kDa and a pI between 4.5 and 5.5 were
detected by both Ig014 and Ig044. Another highly expressed protein spot (no. 27) was detected by Ig044, only. The rectangles indicate the areas
magnified in C. C: Overlay of spots detected by Ig014 and Ig044, respectively, and the corresponding regions of the nurse-like cell protein map in
Figure 1A. Delta 2D software (Decodon) was used for analysis. The magnified regions correspond to the highlighted regions from figure 1A and B.
Overlapping spots are depicted in brown/black and marked by black arrows whereas spots which were only present on the Coomassie stained
protein maps from Figure 1A are depicted in blue.
doi:10.1371/journal.pone.0015992.g001
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Because vimentin was shown to be recognized by both subset 1
antibodies, we focused further evaluation and functional studies on
this antigen.
Vimentin is highly expressed and can be detected in the
supernatant of stromal cells
To corroborate the finding that vimentin functions as an
antigen recognized by stereotyped CLL BCRs of subset 1, we
further explored its interaction with a broader range of protein
extracts from stromal and control cells and correlated it with the
interaction pattern of a commercially available anti-vimentin
antibody. We generated protein extracts from the following cell
types: i.) human cell lines expressing no vimentin (MCF-7) or very
low levels of vimentin (HEK293T, HeLa); ii.) the mouse stromal
cell line M210B4 which is used to support primary human CLL
cells in culture; iii.) primary NLC extracts from the peripheral
blood of three patients with CLL. Protein extracts were separated
by SDS-PAGE and subjected to Western blotting using Ig014 and
a commercially available vimentin antibody as primary antibodies
(Figure 2A). Detection with an anti-b-actin antibody revealed
similar signals in each of the lanes, confirming that equal amounts
of protein had been loaded. The soluble Ig014 BCR detected
vimentin at the same pattern as a commercially available anti-
vimentin antibody albeit at lower sensitivity. Vimentin was
detected in all stromal cell-derived protein extracts, whereas a
much weaker signal was obtained for HEK293T and HeLa cells,
as expected (Figure 2A). Both antibodies did not detect specific
signals in the protein extract from the vimentin-negative cell line
MCF-7 (Figure 2A). The commercial anti-vimentin antibody
showed a somewhat weaker signal for vimentin in the M210B4
mouse cell line extract which we attributed to the lower reactivity
of this antibody with rodent vimentin than with human vimentin
as described previously for this antibody [47]. Interestingly, Ig014
reacted much stronger with stroma-derived vimentin as comp-
ared to vimentin from other cell lines, possibly indicating that
stroma-specific post-translational modifications could be preferen-
tially recognized by this CLL BCR.
To prove that Ig014 interacts with vimentin also in its native
conformation, immunoprecipitations of proteins from NLC
protein extracts were performed. Ig014 was incubated with
protein extracts from NLCs proven to express vimentin and then
immunoprecipitated using protein-G sepharose beads. Precipitates
were analyzed by Western blotting for the presence of vimentin
using the Ig014 immunoglobulin or the commercial anti-vimentin
antibody for detection. The blots showed clearly that Ig014
precipitated vimentin in its native conformation from NLCs. In
contrast, no vimentin could be detected when control protein
extracts were used for immunopreciptation (Figure 2B).
We reasoned that if stroma-derived vimentin serves as an antigen
recognized by CLL cells, it is necessary that vimentin is at least
partially expressed on the surface of and/or secreted and/or shed by
stromal cells. In fact, it has been shown that macrophages can
secrete vimentin and display it on their surface when activated by
infectious agents [48]. To verify this for the CLL patient-derived
NLCs, we immunoprecipitated both a supernatant from NLCs and
a control supernatant from HeLa cells with Ig014. Vimentin was
Table 2. Identification of nurse-like cell proteins recognized by CLL BCRs Ig014 and Ig044 by mass spectrometry.*
S. No. Detecting BCR Protein Score Protein Name Protein MW Protein PI Peptide Count
2 Ig014, Ig044 647 Vimentin 53619 5.06 27
3 Ig014, Ig044 553 Vimentin 53619 5.06 27
4 Ig014, Ig044 318 Vimentin 53619 5.06 24
5 Ig014, Ig044 641 Vimentin 53619 5.06 28
6 Ig014, Ig044 702 Vimentin 53619 5.06 27
7 Ig014, Ig044 753 Vimentin 53619 5.06 28
8 Ig014, Ig044 633 Vimentin 53619 5.06 24
9 Ig014, Ig044 594 Vimentin 53619 5.06 29
10 Ig014, Ig044 108 Vimentin 53619 5.06 9
11 Ig014, Ig044 618 Vimentin 53619 5.06 28
12 Ig014, Ig044 120 Vimentin 53619 5.06 10
13 Ig014, Ig044 634 Vimentin 53619 5.06 32
14 Ig014, Ig044 618 Vimentin 53619 5.06 28
15 Ig014, Ig044 123 Vimentin 53619 5.06 8
17 Ig014, Ig044 707 Vimentin 53619 5.06 33
18 Ig014, Ig044 582 Vimentin 53619 5.06 27
19 Ig014, Ig044 409 Vimentin 53619 5.06 21
20 Ig014, Ig044 815 Vimentin 53619 5.06 31
21 Ig014, Ig044 560 Vimentin 53619 5.06 33
22 Ig014 289 Vimentin 53619 5.06 18
23 Ig014, Ig044 565 Vimentin 53619 5.06 23
24 Ig014 661 Vimentin 53619 5.06 27
27 Ig044 371 Calreticulin 48112 4.2 27
*S. No. denotes sample number, MW denotes molecular weight, PI denotes isoelectric pH.
doi:10.1371/journal.pone.0015992.t002
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detected, albeit at low levels, in precipitates only if NLC supernatant
was used for the immunoprecipitation (Figure 2B). No vimentin
could be precipitated from the control supernatant.
Vimentin is displayed on the surface of viable stromal
cells
The data described above shows that vimentin is present in the
supernatant of NLCs which could be due to active secretion,
membrane shedding, or as a result of NLC apoptosis. To
investigate whether vimentin is indeed also detectable on the
plasma membrane of stromal cells, we performed immunofluo-
rescence stainings on NLCs and the mouse stromal cell line
M210B4 using confocal microscopy. Both Ig014 and the vimentin
antibody yielded a strong cytoplasmic and membrane signal in
NLCs and M210B4 cells (green, Figure 3A and B) which partially
matched the signal of phalloidin-Alexa 594 reacting with
cytoplasmatic and membrane-bound actin (red, Figure 3A and
B). To further determine whether the staining observed at the
edges of the cells indicated the presence of vimentin on the
extracellular side of the plasma membrane, we performed
immunofluorescence on non-permeabilized stromal cells. Indeed,
membrane-associated vimentin staining was also detected in non-
permeabilized stromal cells (green "corona", Figure 4A), implying
that some vimentin is displayed on the outer surface of the cell.
Figure 2. CLL B-cell receptor Ig014 recognizes and immunoprecipitates vimentin from stromal cell protein extracts and culture
supernatants. A: Vimentin is recognized in various stromal cell protein extracts by recombinant CLL BCR Ig014 and a commercially available
vimentin-antibody. Protein extracts were generated from human cell lines expressing no vimentin (MCF-7) or low levels of vimentin (HEK293T, HeLa)
as well as protein extracts from the vimentin-expressing mouse stromal cell line M210B4 and from NLCs of three patients (I, II, III) with CLL. Protein
extracts were separated by SDS-PAGE and subjected to Western blotting using Ig014 or a commercially available vimentin antibody for detection. A
loading control was performed by staining with an anti-b-actin antibody. B: Vimentin can be immunoprecipitated from nurse-like cell protein extracts
and supernatant. Immunoprecipitations were performed from a nurse-like cell extract (NLC) and supernatant (SN) using Ig014 and sepharose-G beads
as described in the materials and methods section. A HeLa cell extract and HeLa supernatant was used as a negative control. Precipitates were
separated by SDS-PAGE and subjected to Western blotting using Ig014 or a commercial anti-vimentin antibody as primary antibodies. Note that in
the left panel the light (LC) and heavy chains (HC) of the Ig014 immunoglobulin used for immunoprecipitation is also detected because an anti-
human immunoglobulin secondary antibody was used when Western blot staining was done with Ig014 as the primary antibody.
doi:10.1371/journal.pone.0015992.g002
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Figure 3. Stromal cells express high amounts of vimentin which can be immunostained with the CLL B-cell receptor Ig014. A:
Visualization of vimentin expression in M210B4 stromal cells and nurse-like cells (NLC) by immunofluorescence confocal microscopy. M210B4 cells
and NLCs were cultured on coverslips, fixed by paraformaldehyde and permeabilized by Triton-X-100. Vimentin was visualized using a FITC-
conjugated anti-vimentin antibody (green). Cell membranes and cytoplasm were counterstained with Alexa Fluor 594 phalloidin (red). The right panel
shows an overlay of both stainings. Stromal cells are shown at low (upper panel) and high magnification (intermediate panel). B: Visualization of
Ig014 staining of M210B4 stromal cells by immunofluorescence confocal microscopy. Stainings were performed using Ig014 as primary antibody,
followed by secondary detection with an anti-human FITC-conjugated antibody (anti-hu. FITC; green). Cell membranes and cytoplasm were
counterstained with Alexa Fluor 594 phalloidin (red).
doi:10.1371/journal.pone.0015992.g003
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Regarding autoantigen-reactivity of CLL BCRs, it has been
suggested that CLL emerges from B-lymphocytes that have been
primed by (mainly intracellular) autoantigens released or displayed
during apoptosis [33,49]. This may also hold true for vimentin,
that has been shown to be displayed on the surface of cells
undergoing apoptosis [33]. We therefore investigated if the stromal
cells staining positive for membrane-bound vimentin (almost
100% of all stromal cells) were viable at the time of staining or
whether they were undergoing apoptosis at this point. Therefore,
trypan blue and 7-aminoactinomycin (7-AAD) stainings were
performed on the stromal cell layers used for immunofluorescence
just prior to fixation. Of note, less than 1% of stromal cells stained
positive for either trypan blue or 7-AAD, suggesting that the
majority of cells were not apoptotic while displaying vimentin
on the cell surface (Figure 4B). To exclude that the cells were
in very early phases of apoptosis not yet detectable by trypan
blue or 7-AAD staining, we also stained and counted the number
of apoptotic/dead cells on the slide and in the supernatant 24 and
48 hours after the time point when the stromal cells were used for
vimentin immunofluorescence stainings. We assumed that early
apoptotic cells would then be in late phases of apoptosis and thus
detectable in the supernatant and on the slide by stainings with
apoptosis markers. After 24 hours, .99% and after 48 hours,
.97% of the adherent stromal cells were viable and less than 100
dead cells (out of 105 seeded adherent cells) were counted in the
supernatant (Figure 4B, time points "24 h" and "48 h"). This
indicates that at the time point of the vimentin staining, stromal
cells were not undergoing apoptosis und thus vimentin was
displayed ‘‘actively’’ on viable stromal cells.
Stroma blocking with recombinant BCR reduces CLL 014
protection from apoptosis
Stroma-mediated anti-apoptotic effects have so far been mainly
ascribed to the action of cytokines and other anti-apoptotic
Figure 4. Viable stromal cells actively display vimentin on their cell surface. A: Vimentin is displayed on the surface of non-permeabilized
M210B4 stromal cells as visualized by confocal microscopy. Cells were cultured and fixed with paraformaldehyde as above but omitting the
permeabilization step. A FITC-conjugated Vimentin antibody stained the outer surface of the cells (green "corona") as shown in the left panel.
Intracellular counterstaining could not be performed due to the non-permeabilized state of the cells. The right image highlights the cell margins by a
dotted grey line. B: Stromal cells (as used for immunofluorescence stainings, Figure 4A) display vimentin independently of apoptotic events. Cell
viability was assessed before the vimentin staining ("0 h"), as well as 24 and 48 hours later ("24 h" and "48 h"). Less than 1% of cells underwent
apoptosis at time point "0 h" and "24 h" and less than 3% at time point "48 h" as demonstrated by staining with the apoptosis marker 7-AAD
(interspersed purple cells, highlighted by white arrows). Nuclei were counterstained with DAPI (blue). Pictures were taken using conventional
fluorescence microscopy.
doi:10.1371/journal.pone.0015992.g004
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proteins expressed by stromal cells. Having shown that the
stroma-derived antigen vimentin is displayed on the surface of
viable stromal cells, we asked whether this BCR-antigen
interaction can protect CLL 014 cells from apoptosis. Therefore,
CLL 014 cells were cultured alone and on a layer of M210B4
stromal cells blocked with either Ig014 or the control BCR IgGr
at 100 mg/ml. The viability of CLL 014 cells was assessed after
six days of co-culture by trypan blue staining and in a separate
experiment by 7-AAD staining followed by fluorescence-activated
cell sorting (FACS) analysis (Figure 5A and B). In both
experimental approaches, the majority of previously cryopre-
served CLL 014 cells lost viability after six days when cultured
without a protective stromal cell layer (viability approximately
5%). There was a clear anti-apoptotic effect upon CLL cell
cultivation on the stromal cell layer, resulting in 30–40% viable
cells, when the stromal cell layer was blocked with the control
BCR IgGr. When Ig014 was used to block the CLL-stroma
interaction, the viability of CLL 014 cells was significantly lower
(20–25% viable cells), suggesting an anti-apoptotic effect of the
BCR-vimentin interaction on the surface or in the supernatant of
M210B4 stromal cells. Next, CLL 014 cell viability was
determined over a defined time course under the same conditions
as specified above (Figure 5C). The measurement of apoptosis
was performed by FACS analysis using 7-AAD complemented by
annexin V to detect even earlier phases of apoptosis. Therefore,
the percentage of viable CLL 014 cells was slightly lower than in
previous experiments at a comparable time point. As in previous
experiments, CLL 014 cells died rapidly without stromal support
(Figure 5C). The anti-apoptotic effect of the stroma was
significantly inhibited when stromal cells were blocked with the
specific CLL BCR Ig014. This effect wore off after seven days of
culture, when 90% of all co-cultured CLL cells were dead. To
determine if the effect was indeed mediated by vimentin, we
compared the inhibition of the protective stroma effect by BCR
Ig014 with a commercially available anti-vimentin antibody.
Therefore, CLL 014 cells were cultured alone, on a layer of
M210B4 stromal cells, or on stroma cells and blocked with either
control BCR IgGr, BCR Ig014, or the commercial anti-vimentin
antibody with specificity for human and murine vimentin. The
viability of CLL 014 cells was assessed after 12 hours of co-
culture by Annexin/PI staining followed by fluorescence-
activated cell sorting (FACS) analysis (Figure 5D). The protective
stroma effect on CLL cells could be blocked to the same extent
(approximately 40%) by both BCR Ig014 and the vimentin
antibody as compared to unblocked or control antibody-blocked
stroma (p = 0.002). These results suggest that vimentin is
displayed on the surface of stromal cells and provides anti-
apoptotic signals to CLL 014 cells through the BCR. We
reasoned that, alternatively, the reduced viability of CLL cells on
blocked stroma could be explained by the limited stroma-
attachment itself, as a physical contact between stromal and CLL
cells has been shown to be required for stroma-induced anti-
apoptotic effects [7]. To dissect the effects of mere attachment-
related and direct anti-apoptotic effects through the BCR, HEK
293T cells were transfected with a eukaryotic secretory expression
vector encoding vimentin and an empty control vector,
respectively, and used as a "feeder layer" for CLL 014 cells.
HEK 293T cells transiently transfected with the vimentin
encoding vector secreted vimentin in the supernatant (data not
shown). When CLL 014 cells were cultured on this "feeder layer",
the viability was enhanced compared to CLL 014 cells cultured
on HEK 293T cells transfected with an insertless control vector
(Figure 5E), suggesting protective effects of the secreted BCR
antigen.
Discussion
The B-cell receptor and its recognition of antigens may play a
very important role in CLL pathogenesis and progression. Several
antigens that are recognized by CLL B-cell receptors (BCRs) have
been described. Yet, there is only speculation as to where these
antigens are expressed, under which conditions they are exposed
as well as whether – and if so: how – this relates to the interaction
of the malignant lymphocytes with their microenvironment. Many
studies have addressed the protective role of the stroma in CLL
and different cell biological axes have been described to mediate
these effects. These include protection from apoptosis by chemo-
and cytokines, such as the stromal cell-derived factor-1 (SDF-1)
which is secreted by stromal cells and interacts with the chemokine
receptor CXCR4 on CLL cells [4]. After chemokine-mediated
migration to the protective microenvironment, CLL cells attach to
stromal cells via integrins, such as VLA-4 which binds to stromal
VCAM-1 and fibronectin [14,15]. Based on recent studies,
however, there is reason to believe that stroma protection is not
exclusively chemokine-, cytokine- and integrin-mediated but may
also involve signaling through the BCR for antigen. Burger et al.
recently showed that CCL3 and CCL4 expression is induced upon
co-culture of CLL cells with stromal cells and that this can be
blocked by antagonists of the BCR signaling pathway [34].
Moreover, there is evidence that antagonists of the BCR pathway,
such as Syk or Akt inhibitors, can inhibit stroma-mediated
protection from apoptosis [35,50,51,52]. These data led us to
hypothesize that stromal cells may constitute an antigen reservoir
for CLL cells, thus providing not only cytokine- and classical
adhesion molecule-mediated but also BCR-mediated survival
signals.
To test this hypothesis, we cloned and expressed a set of CLL
BCRs expressing common stereotyped HCDR3 sequences (subsets
1, 3 and 7 according to Stamatopoulos [19] and Murray [38]) and
tested the interaction of these antibodies with lysates of a set of
different cell types including stromal cells. We found that two CLL
BCRs belonging to subset 1 [19,38], termed Ig014 and Ig044,
recognize the protein vimentin. One of the antibodies, Ig044, also
interacted with calreticulin. The results of our confocal microscopy
studies suggested that Ig014 interacts with vimentin exposed on
the extracellular side of the plasma membrane of stromal cells.
This BCR-mediated stromal antigen recognition seemed to be
functionally relevant. We found a significant reduction of stroma-
mediated protection from apoptosis in CLL 014 cells when stromal
vimentin was competitively blocked by the CLL BCR or a
commercially available anti-vimentin antibody and found an
enhanced protective effect when feeder cells were forced to secrete
vimentin. Therefore, our results prove for the first time that a
stroma-derived antigen adds to the effect of stroma-mediated
protection from apoptosis by BCR binding.
The CLL BCRs Ig014 and Ig044 use different heavy and light
chain genes; yet, both of them are categorized as subset 1
antibodies [19,38] as they express highly homologous HCDR3
sequences. Considering this, their common reactivity with
vimentin is presumably mediated by their shared HCDR3,
whereas calreticulin could be recognized by other regions of
CLL BCR Ig044 such as CDR1, CDR2 or framework regions.
Interestingly, vimentin and calreticulin have physiological and
pathophysiological features in common. Both proteins are
multifunctional, primarily intracellular proteins highly expressed
in NLCs. Vimentin, a class III cytoskeletal protein in cells of
mesenchymal origin, locates to the cytoplasm whereas calreticulin
is expressed in the endoplasmic reticulum. Translocation to the
plasma membrane has been described for both proteins
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Figure 5. Stromal cell displayed or secreted antigen protects CLL 014 cells from spontaneous apoptosis. A and B: Soluble recombinant
B-cell receptor Ig014 competes stromal cell-mediated CLL 014 cell protection from spontaneous apoptosis. CLL 014 cells were cultured alone or in co-
culture with the stromal cell line M210B4. B-cell receptor-mediated stroma-CLL cell interactions were blocked by the recombinant B-cell receptor
Ig014 or the control immunoglobulin IgGr. After six days of culture, CLL viability was assessed either by trypan blue staining (A) or by FACS analysis
using 7-AAD (B). The diagrams show the percentage of viable CLL 014 cells at this time point (data are means of triplicates [A] or duplicates [B] +/2
SEM). C: Time course of CLL 014 apoptosis on stroma blocked with the recombinant B-cell receptor Ig014 and with the control IgGr. Under the
experimental conditions described in panel A and B of this figure, CLL 014 apoptosis was measured at different time points. To detect early and late
phases of apoptosis, the measurement included staining with annexin V and 7-AAD followed by FACS analysis (Data are means of duplicates +/2
SEM). D: Stromal cell-mediated CLL 014 cell protection can be competed by a known anti-vimentin antibody. CLL 014 cells were cultured alone, in co-
culture with the stromal cell line M210B4 or with stroma cells blocked with either control B-cell receptor IgGr, CLL B-cell receptor Ig014, or a
commercially available rabbit anti-mouse/human vimentin antibody. Apoptosis was measured after 12 hours of culture by staining with annexin V
and PI followed by FACS analysis. CLL 014 cell viability reductions under blocked stroma conditions were calculated as relative values with unblocked
stroma support (set to 100%). Data are means of duplicate experiments +/2 SEM. E: A vimentin secreting "feeder layer" exerts a protective effect on
CLL 014 cells. CLL 014 cells were cultured on a layer of HEK 293T cells transfected with a vimentin encoding secretory eukaryotic expression vector or
an empty control vector. The viability of CLL 014 cells was determined at different time points of the co-culture experiment by FACS analysis using 7-
AAD (data means of duplicates +/2 SEM).
doi:10.1371/journal.pone.0015992.g005
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[48,53,54,55]. In addition to their physiological roles, vimentin
and calreticulin are targets in autoimmune conditions, like
rheumatoid arthritis [56,57]. During apoptosis, vimentin can be
exposed on the cell surface and triggers the generation of
autoantibodies in some patients with rheumatoid arthritis [57].
Independently of apoptotic events, vimentin can be actively
secreted and exposed on the extracellular side of the plasma
membrane as it has been shown recently for activated macro-
phages [48]. Interestingly, macrophages and NLCs are similar cell
types in that they both derive from monocytes. Vimentin has been
described as an antigen recognized by different stereotyped
(IGHV3-30-subset 32 [33], IGHV4-39-subset 8 [49]) and non-
stereotyped (IGHV3-30 [33]) CLL BCRs. This finding has
strengthened the hypothesis that CLL BCRs may frequently, if
not generally, recognize molecular binding motifs on apoptotic
cells, also taking into account reactivities with other proteins
exposed on apoptotic cell surfaces. While this hypothesis may hold
true, our data indicate that there may also be active secretion of
proteins by viable stromal cells, potentially accounting for chronic
antigen stimulation through the BCR.
CLL is a heterogeneous condition with some patients living for
decades after diagnosis whereas others succumb rapidly to the
disease despite therapy. Patients 014 and 044 of our study express
a BCR with a stereotyped HCDR3 sequence ([19,38]). This class
of receptors is associated with an aggressive clinical course and
effective treatment options are an unmet clinical need especially
for this group of patients. As we improve our understanding of the
protective role of accessory stromal cells in CLL, the microenvi-
ronment becomes an increasingly attractive biological target for
novel treatment strategies in CLL.
Supporting Information
Figure S1 CLL B-cell receptor binding to protein
extracts from stromal cells. Primary nurse-like cells (NLCs)
and the murine stromal cell line M210B4 alone or after co-culture
with primary CLL cells were lysed and separated by one-
dimensional gel electrophoresis. The reactivity of polyclonal IgG
and the CLL BCRs Ig014, Ig015 and Ig022 was tested by Western
blot analysis using the BCR as primary antibody followed by
HRP-based secondary detection. Ig014 recognized a range of
proteins between 45 and 57 kDa in size which were not
recognized by the other BCRs.
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